Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADIGM-HF: Entresto vs Enalapril in HFrEF
NCT01035255Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 47
01
Overview
A Phase 3 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Novartis. Started Dec 2009; status: terminated.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT01035255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01035255.